Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-09-07
1991-10-22
Friedman, Stanley J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3141
Patent
active
050596128
ABSTRACT:
The invention relates to a method of treating dementia, such as cerebro-vascular dementia, for example, multiple infarct dementia and amyloid angiopathic dementia, cerebro-parenchymatous dementia, such as Alzheimer's dementia and Pick's disease, and dementia caused by brain tumor, hydrocephalus, hepatic meningitis, cerebral trauma, or cerebral function disorders, comprising administering rolipram.
REFERENCES:
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4153713 (1979-05-01), Huth et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
Horowski et al., "Clinical Effects of the Neurotropic Selective cAMP Phosphodiesterase Inhibitor Rolipram in Depressed Patients . . . ", Curr. Therap. Res. 38:23-29, Jul. 1985.
Fujiwara Michihiro
Ichimaru Yasuyuki
Imanishi Taiichiro
Konno Fukio
Sawa Aiko
Friedman Stanley J.
Schering Aktiengesellschaft
LandOfFree
Anti-dementia drug does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-dementia drug, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-dementia drug will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-108785